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Abstract
We observed an unusually large subependymoma in a female patient with congenital aniri-
dia.Toanalyzethegeneticmechanismsoftumorigenesis,weﬁrstexaminedthepairedbox6
(PAX6)geneusingbothtumortissueandperipherallymphocytes.Tumorsuppressoractivity
has been proposed for PAX6 in gliomas, in addition to its well-known role in the eye
development. Using genomic quantitative PCR and loss of heterozygosity analysis, we
identiﬁed hemizygous deletions in the 5′-region of PAX6. In lymphocytes, the deletion
within PAX6 spanned from between exons 6 and 7 to the 5′-upstream region of the gene, but
did not reach the upstream gene, RNC1, which is reported to be associated with tumors.The
subependymomahadanadditionaldenovodeletionspanningfromtheintron4tointron6of
PAX6, although we could not completely determine whether these two deletions are on the
same chromosome or not. We also examined other potentially relevant tumor suppressor
genes: PTEN, TP53 and SOX2. However, we detected no exonic mutations or deletions in
these genes. Collectively, we speculate that the defect in PAX6 may have contributed to the
extremely large size of the subependymoma, due to a loss of tumor suppressor activity in
glial cell lineage.
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INTRODUCTION
Subependymoma is a rare, indolent benign tumor of the central
nervous system that commonly occurs in middle-aged or elderly
men, with an incidence of approximately 0.5% of all intracranial
neoplasms (15). The majority of tumors arise in the fourth (60%)
and lateral ventricles (30%), and more rarely in the third ventricle,
the septum pellucidum and the spinal cord (18). Many subependy-
momas remain asymptomatic throughout life and are found only
incidentally by autopsy or imaging.The pathogenesis of the tumor
remains largely unclear.
We observed an extremely rare case of a giant subependymoma
in a young female with familial congenital aniridia that spans three
generations. Familial congenital aniridia is a hereditary disease
transmitted in an autosomal dominant fashion and is caused by
genetic defects within the paired box 6 (PAX6) gene in about 90%
ofcases(8).ThePAX6geneislocatedatchromosome11p13,spans
22 kb, consists of 14 exons (including an alternatively spliced exon
5a that encodes 14 amino acids) and encodes a protein of 422
amino acids. PAX6 is a transcription factor that is involved in
multiple developmental pathways and is expressed early in the
development of the eye, numerous regions of the brain and the
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gliomasuppressorgene,basedontwomainfacts:theexpressionof
PAX6 correlates with astrocytoma grade and survival (24) and
PAX6 suppresses the growth of glioblastoma cells in vitro (25). It
has also been reported that PAX6 inhibits proliferation of astrocyte
progenitors and promotes their maturation in rodents (16).
Although the precursor cells of subependymomas have not been
conclusively identiﬁed, some candidates have been proposed: sub-
ependymal glia (1), astrocytes of the subependymal plate, ependy-
mal cells (12) and a mixture of astrocytes and ependymal cells (4).
Since there have been no reports of subependymoma occurring
in any hereditary diseases, we set out to perform this study in the
hope that analyses of the current case with the complication of eye
abnormalities may help determine the mechanisms responsible for
the huge growth of the subependymoma.
MATERIALS AND METHODS
Patient
The patient describes a 27-year-old female after admission to our
hospital(KanazawaUniversityHospital).Shewasbornatfullterm
after an uneventful pregnancy. Five months before admission, she
complained of chronic headaches and nocturnal urinary inconti-
nence. In March 2005, she was admitted to our hospital because
of memory disturbances, unsteady gait and visual loss. Neuro-
ophthalmologicexaminationrevealedbilateralaniridia,blepharop-
tosis, mild cataract, papilledema, horizontal gaze nystagmus and
marked and nonadjustable visual loss. Similar ocular disturbances
were observed in her mother and her elder brother, but their irises
were only partially defective and irregularly shaped. The maternal
grandfather and three of ﬁve maternal siblings were said to have
oculardisturbancesbutthedetailsareunknown(Figure 1AandB).
Their abnormalities of the eye had probably been overlooked
because they live in a rural part of Japan and had no previous need
for a specialist medical examination. Magnetic resonance imaging
(MRI) on admission revealed a large tumor (9 ¥ 7 ¥ 6 cm) located
inthethirdtobilaterallateralventricles(Fig. 1C).Scatteredmicro-
calciﬁcations were detected on computed tomography (CT). She
underwent surgery via the anterior transcallosal approach. The
tumor stemmed from the septum pellucidum and was well demar-
cated from the ventricular wall except for the right anterior horn.
The tumor was grayish, rubbery, unsuckable in consistency and
bled minimally. Intraoperative pathologic diagnosis indicated a
subependymoma and gross total resection was performed with an
Ultrasonic Surgical Aspirator (Sonopet, Miwatec Co., Ltd, Aichi,
Japan).
Histological examination
Archival parafﬁn sections were stained with hematoxylin–eosin
(HE) and the monoclonal antibody MIB-1 (DakoCytomation,
Glostrup, Denmark). The histological type and grade of tumors
werere-evaluatedaccordingtotheWorldHealthOrganizationclas-
siﬁcation system.
Direct sequencing
Genomic DNA was isolated from parafﬁn-embedded tumor tissue
using RecoverAllTMTotal NucleicAcid Isolation Kit (Applied Bio-
systems, Foster City, CA) that contains protease to break down
cross-linked proteins, and peripheral lymphocytes from the patient
and from ﬁve control subjects (one male and ﬁve females) by
standard methods. All the exons and exon/intron boundaries of
PAX6, PTEN, TP53 (gene for p53) and SOX2 were screened for
polymorphisms by direct sequencing of polymerase chain reaction
(PCR) products. PCR was performed under the conditions
described in the Supplementary Information. Direct sequencing of
PCR products was performed using the BigDye Terminator v3.1
Cycle Sequencing kit (Applied Biosystems) and the ABI PRISM
3730xl Genetic Analyzer (Applied Biosystems). Polymorphisms
were detected with the SEQUENCHER program (Gene Codes
Corporation, Ann Arbor, MI). The information on primers,
enzymes and PCR conditions used for ampliﬁcation is described in
Tables S1 and S2.
Genomic quantitative PCR
All of the insertions/deletions within each gene and in intergenic
regions were analyzed by real-time genomic quantitative PCR
using the TaqMan method (Applied Biosystems). The MLC1 gene
at chromosome 22q13.33 was used as a normal copy number
control gene. For quality control, PFKFB1 on chromosome
Xp11.21 was used to see whether our genomic quantitative PCR
could accurately detect differential dosage of the X chromosome
between male and female control samples. No copy number poly-
morphisms have been documented within these genes in the Japa-
nesepopulation.ForthegenomicquantitativePCR,DNAsolutions
were ﬁrst quantiﬁed by an ultraviolet spectrophotometer and
further quantiﬁed by a TaqMan RNase P Detection Reagent kit
(Applied Biosystems). Sequences of primers for individual gene
regions are listed inTable S2. Detailed information including PCR
conditions is available upon request.
Figure 1. Patient’s clinical information. A. Family structure of a patient
with aniridia and subependymoma. Black symbols indicate individuals
with aniridia. Squares represent males and circles represent females. B.
Biomicroscopic observations of the patient with aniridia and subependy-
moma. C. Preoperative magnetic resonance imaging scans showing a
tumor originating from the septum pellucidum. Left: FLAIR (ﬂuid attenu-
ated inversion recovery) mode, Right: T1-weighted image after adminis-
tration of contrast media (Gd). The size of the tumor was 9 ¥ 7 ¥ 6c m
and the tumor contained multiple small calciﬁcations and cysts. The
tumor was slightly hypointense on a T1-weighted image, hyperintense
on a T2-weighted image and markedly hyperintense on a FLAIR image
(this image suppresses signals from cerebrospinal ﬂuid and can obtain
clear images of periventricular tumors). Tumor enhancement after
administration of contrast media (Gd) was minimal. D. Photomicrograph
of the stained tumor showing cell nests and microcysts scattered in the
glioﬁbrillary background (stained with hematoxylin and eosin, original
magniﬁcation: 200¥). E. Photomicrograph of the tumor tissue stained
with MIB-1. MIB-1-positive cells (their nuclei are colored in dark brown)
are shown by arrow heads (original magniﬁcation: 200¥).

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from tumor tissue
Total RNA was extracted from the tumor tissue sample using
RecoverAllTM Total Nucleic Acid Isolation Kit (Ambion, Austin,
TX, USA). Single stranded cDNA was synthesized using High
Capacity RNA-to-cDNA Master Mix (Applied Biosystems).
Reverse transcription PCR (RT–PCR) ampliﬁcation was per-
formed in a nested manner: the ﬁrst PCR was done using the
primers set at exons 4 and 7. The second PCR was done using the
primers placed on exons 5 and 7. The sequences of the PCR prod-
ucts were veriﬁed by direct sequencing. The detailed information
of primer sequences and PCR conditions is available upon request.
Analysis of loss of heterozygosity (LOH)
To examine the LOH, we genotyped by direct sequencing the 73
single nucleotide polymorphisms (SNPs) shown in Figure 4 and
Table S7, using DNA from the patient tumor tissue, lymphocytes
from the patient and DNA from the six control subjects. Detailed
information including PCR primers and conditions is available
upon request.
Cytogenetic examination
Peripheral lymphocytes were cultured and chromosomes were
G-banded using trypsin Giemsa (GTG) staining. Karyotyping was
performed on 30 metaphase spreads per subject (21).
RESULTS
Histological examination of subependymoma
Histologic diagnosis indicated pure subependymoma with no other
glioma component, mitosis or cellular atypism (Figure 1D and E).
The MIB-1 index was less than 1%. The MIB-1 index shows the
percentageofproliferatingcells,inwhichproliferativeactivitywas
assessed by use of the monoclonal antibody MIB-1
Sequencing and genomic quantitative PCR
analyses of PAX6
To examine mutations of the PAX6 gene, we performed direct
sequencing of all the exons and exon/intron boundaries of the gene
using DNA from the patient’s tumor tissue and lymphocytes. We
detected no mutations of PAX6 in either sample.
Next, to examine allelic loss of PAX6 in the patient’s tissue,
we performed genomic quantitative PCR with probes designed
to exons 13, 7, 6, 5, 2 and 1a of PAX6 (Figure 2), and around
rs11031497 [64 296 base pairs (bp) upstream from the A of the
ATG codon of PAX6 and 235 016 bp downstream of the 3′-end of
thelastexonofRCN1]andrs12420599(251 262 bpupstreamfrom
theATGcodonofPAX6and48 050 bpdownstreamofthe3′-endof
RCN1) (Figure 3). In the lymphocyte genome, hemizygous dele-
tionswereevidentwithprobestoexons2and1a,indicatingthatthe
deleted region spans from between exons 5 and 2 to downstream of
rs11031497 (Table 1). In the tumor tissue, the probe to exon 7
showed no evidence of deletion and the probe to exon 6 displayed
Figure 2. Genomic structures of the three PAX6 isoforms. In isoform
a-1, A of the ATG codon is located at nucleotide (nt) position 470 and the
end of the stop codon at nt 1738, counted from the 5′-end of the ﬁrst
exon. In isoform a-2, A is located at nt 534 and the end of the stop codon
at nt 1802. In isoform b, A is located at nt 436 and the end of the stop
codon at nt 1746. The positions where we performed gQ–PCR are
shown in red. The genomic structure of PAX6 is based on the University
of California Santa Cruz (UCSC) March 2006 draft assembly of the
human genome database (http://genome.ucsc.edu/cgi-bin/hgGateway?
org=human). Information on known single nucleotide polymorphisms
was obtained from the National Center for Biotechnology Information
(NCBI) database (http://www.ncbi.nlm.nih.gov/). At the bottom, deleted
portions are shown. Solid lines show experimentally veriﬁed regions.
Dashed lines show that the breakpoints are located somewhere in the
regions. Abbreviations: PAX6 = paired box 6 gene; gQ–PCR = genomic
quantitative polymerase chain reaction.
Giant Subependymoma in a Patient with Aniridia Maekawa et al
1036 Brain Pathology 20 (2010) 1033–1041
© 2010 The Authors; Brain Pathology © 2010 International Society of Neuropathologya signature of deletion (Table 1). Therefore, it seemed that in the
tumor cells, the PAX6 deletion extends more to 3′-direction than
that of the lymphocyte genome, or the tumor genome has an addi-
tional de novo deletion. To address this issue, we performed addi-
tional genomic quantitative PCR analyses with probes designed to
intron 2, exon 3, intron 3, exon 4 and intron 4 (Figure 2). These
resultsshowthatthetumorgenomehastwodistinctPAX6deletions
(Table 1): the one is the same to that of normal somatic cells (albeit
we did not examine whether the 5′-break points of tumor and
somatic cell genomes are on the same position), and the other de
novo one spans from the intron 4 to intron 6 of PAX6 gene
(Figure 2).We also attempted to determine the deletion boundaries
of the de novo deletion by PCR, but we failed to amplify any
genomic fragments under multiple conditions tested, presumably
because it is difﬁcult to completely eliminate peptide fragments
bound to DNA, which is generated by formaldehyde ﬁxation of
tumor tissue; we cannot amplify such DNA of relatively long size
by PCR that peptide fragments are attached to.
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Figure 3. Analysis of loss of heterozygousity around PAX6 on chromo-
some 11p from the patient’s tumor tissue and lympocytes and six
control samples. Stretches of homozygous SNPs are encircled by dotted
lines. Exons are shaded. Minor allele is deﬁned as a frequency of <5%.
The positions of SNPs located at the 5′-upsteam region of PAX6 are
shown as distances from the A of the ATG codon located in exon 4 of the
gene (also see Figure S1). Abbreviations: PT = patient’s tumor tissue;
PB = patient’s lymphocytes; C = control; gQ–PCR = genomic quantita-
tive polymerase chain reaction; PAX6 = paired box 6 gene; SNPs = single
nucleotide polymorphisms.
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tumor tissue
Next,wesetouttodeterminewhetherthetwodifferentdeletionsof
PAX6 in tumor genome are on the same chromosome or on differ-
ent chromosomes. The 5′-side (germline) deletion involves the
promoter region and the ﬁrst two exons, making the mRNA tran-
scriptionimpossible(Figure 2).Therefore,ifthetwodifferentdele-
tions were located on the same chromosome, we could not amplify
any portions of PAX6 transcript from the tumor tissue including the
region that corresponds to the 3′-side de novo deleted genomic
interval. Our RT–PCR analysis detected the cDNA stretch that
spans from exon 5 to exon 7 (Figure 4). These results suggest that
the two deletions seen in the tumor genome are likely to be located
on the same chromosome in tandem. However, we cannot
completely exclude the possibility that the detected PCR products
stemmed from the contaminated normal cells in the tumor
tissue.
LOH analysis around PAX6 locus
We examined the genotypes of 73 SNPs mapped in the interval
spanning from the last exon 13 of PAX6 to the 5′-region of the
neighboring RCN1 gene (Figure 3). We included all known SNPs
that mapped in the region from intron 2 to the exon 13, to conﬁrm
the genomic quantitative PCR results for the position of the break-
point in tumor cells. In both the tumor and lymphocyte samples,
the homozygosity of SNPs ensued from the most 3′-end SNP
examined,e.g.rs3026398–rs12420599.The5′-neighboringSNPto
rs12420599, rs224634 showed heterozygosity in both samples. In
some of the ﬁve control samples (lymphocytes), heterozygous
genotypes of SNPs were detected in the described genomic stretch
(Figure 3). These results suggest that (i) the 3′-end of the deleted
region from the patient lymphocytes is within intron 2 of PAX6 as
deduced from the combined genomic quantitative PCR and LOH
data, and (ii) the 5′-ends of the deleted regions are the same or very
close to each other in the tumor and normal somatic cells of the
patient. In addition, the results indicate that the genomic deletions
occurring in the patient do not involve the RCN1 gene or are
unlikely to involve the promoter region of the RCN1 (the distance
between rs224634 and the 5′-end of RCN1 is 33 256 bp). From
LOHanalysis,wecouldnotobtainfurtherinformativedatabeyond
quantitative genomic PCR analysis, regarding the 3′-ends of the
two deletions, because there were no heterozygous SNPs in the
Table 1. Genomic quantitative–PCR of PAX6. Abbreviations: PCR = polymerase chain reaction; PAX6 = paired box 6 gene.
Region Patient’s tumor Patient’s lymphocyte Control (Male) Control (Female)
rs12420599 (Chr11: 32 035 797)* 1.13 1.40 1.32 1.45
rs11031497 (Chr11: 31 848 831)* 1.07 1.31 1.32 1.41
PAX6_Exon 1a 0.59 0.64 1.26 1.39
PAX6_Exon 2 0.60 0.59 1.22 1.29
PAX6_Intron 2 0.42 0.61 1.21 1.34
PAX6_Exon 3 1.36 1.36 1.30 1.29
PAX6_Intron 3 1.11 1.28 1.28 1.40
PAX6_Exon 4 1.19 1.29 1.30 1.44
PAX6_Intron 4 1.04 1.29 1.29 1.43
PAX6_Exon 5 0.67 1.30 1.35 1.49
PAX6_Exon 6 0.62 1.34 1.40 1.51
PAX6_Exon 7 0.95 1.33 1.41 1.57
PAX6_Exon 13 0.91 1.41 1.43 1.65
Gray shaded boxes show signature of deletion.
*The positions are based on the UCSC database (http://genome.ucsc.edu/cgi-bin/hgGateway?org=human).
100 bp
  ladder
Patient's
tumor
Positive
control
Figure 4. RT–PCR analysis of PAX6 transcript from tumor tissue. Total
RNA was extracted from tumor tissue and converted to cDNA. The ﬁrst
PCR was done using primers designed to exon 4 and exon 7. The second
(nested) PCR was done using primers set at exon 5 and exon 7. Left
lane: 100 bp ladder; middle lane: nested PCR product; right lane: a posi-
tive control (human brain Marathon cDNA from BD Biosciences, San
Jose, CA). The sequence of PCR product was veriﬁed by sequencing.
Abbreviations: RT–PCR = reverse transcription PCR; PCR = polymerase
chain reaction; PAX6 = paired box 6 gene.
Giant Subependymoma in a Patient with Aniridia Maekawa et al
1038 Brain Pathology 20 (2010) 1033–1041
© 2010 The Authors; Brain Pathology © 2010 International Society of Neuropathologyinterval3′-downstreamofintron2[andtherearenoknownSNPsin
the genomic stretch from exon 5 to exon 7 (Figure 3)].
Screening of the tumor related genes: PTEN,
TP53 and SOX2
To further evaluate the potential genomic abnormalities associated
with this subependymoma, we examined three tumor-related
genes: PTEN, TP53 and SOX2.We performed direct sequencing of
all exons and exon/intron boundaries of the three genes from
patient tumor tissue and lymphocytes and lymphocytes from six
control subjects. In this analysis, we detected two novel SNPs (one
in intron 1 and the second in intron 8) within PTEN (Table S3). A
novel C allele at IVS4-137 was found in the patient’s tumor. The
other novel 8T allele at IVS4-30-37 (insT: 9T is already registered)
was found in the patient’s tumor. We deposited these novel SNPs
into the NCBI database, and obtained the I.D. ss161110057 and
ss161110058, respectively. However, there were no exonic muta-
tions in any of the samples. In addition, the genotypes of the exam-
ined SNPs located between the ﬁrst and last intron of PTEN were
all heterozygous in the tumor sample (Table S3), excluding the
possibility of allelic deletion within the gene.
With regards to the TP53 gene, sequencing detected no muta-
tions in either the patient’s tumor or lymphocyte samples, or in the
two control samples. The genotypes of all the SNPs examined in
the patient were homozygous in the tumor tissue and lymphocytes,
giving no information about the genomic deletions (Table S4). We
conﬁrmed the absence of any deletions using real-time PCR to
quantify genomic DNA templates from exon 1, intron 6 and exon
11 (the last exon) (Table S5).
The SOX2 gene consists of one exon. We performed genomic
quantitative PCR using probes designed to the 5′and the 3′-regions
of exon1. The results showed no evidence of genomic deletions
(Table S6).
Cytogenetic analysis and genomic quantitative
PCR analyses of chromosomes 6q and 14q
It was reported that there were trisomy of chromosome 7, mono-
somy of chromosome 8 and partial losses on chromosome 6q and
chromosome 14q in some subependymoma cases (10) (Figure S3).
Therefore we examined chromosomal aberrations. Karyotype
analysis of lymphocytes did not detect any chromosomal rear-
rangements, aneuploidies and gross deletions and duplications
(Figure S1). In addition, we performed genomic quantitative PCR
placing probes at reported regions chromosome 6q and chromo-
some14q(9)(Table 2).Theresultsshowednoevidenceofgenomic
deletion in chromosomal 14q, but showed that there is a region of
hemizygous loss in chromosome 6q (Table 2).
DISCUSSION
Here, we report the ﬁrst case of subependymoma developed in a
patient with a hereditary disease (aniridia).The size of subependy-
moma was unusually huge. We also examined the underlying
mechanisms and detected a deletion in the 5′-region of PAX6 in
lymphocytes and tumor cells and an additional de novo deletion in
the tumor cells from the patient. Postoperatively, the patient was
slightly hemiparetic on the left, but recovered completely after
1 month. A ventriculoperitoneal shunt procedure was performed
for delayed hydrocephalus.Three years after the operation, an MRI
revealed no tumor recurrence and she recovered fully from her
neurological symptoms. During this time, she had gotten married
and delivered a full-term baby boy who also displayed an irregular-
shaped iris and spontaneous nystagmus (Figure 1A).
While the familial aniridia can be explained by the PAX6 dele-
tion,itislikelyother/additionalgeneticmechanism(s)playedarole
in the onset and extraordinarily large growth of the subependy-
moma. Therefore, we examined three other tumor suppressor
genes, PTEN, TP53 and SOX2, which are relevant to either glioma
or PAX6 function. PTEN is a major tumor suppressor gene that is
inactivated in 50% of high-grade gliomas (5). PAX6 and PTEN
expression levels are deemed to be two independent and powerful
prognostic markers for the outcome of patients with astrocytic
malignant gliomas (24). The mutational inactivation of TP53 has
been reported in progressive glioblastomas (5). SOX2 encodes a
transcription factor, and this protein is known to act by forming a
heterodimer with PAX6 (9). SOX2 is a marker for gliomas in early
and progressed stages, and it plays a fundamental role in the main-
tenance of the self-renewal capacity of neural stem cells after they
have acquired cancer properties (6). However, the patient had
no mutations or deletions in these genes ruling out a possible
contribution to the development of the giant subependymoma.
In addition, karyotype analysis showed that there are no gross
Table 2. Genomic quantitative RT–PCR analyses of chromosomes 6q and 14q. Abbreviation: RT–PCR = reverse transcription polymerase chain
reaction; Chr = chromosome.
Probe* Patient’s tumor Patient’s blood Control (male) Control (female)
Chr6_1 (76 693 510–76 693 525) 1.51 1.37 1.28 1.17
Chr6_2a (79 053 906–79 053 927) 0.63 0.69 1.40 1.34
Chr6_2 (79 054 011–79 054 030) 0.42 0.57 1.82 1.32
Chr6_2b (79 054 109–79 054 128) 0.64 0.73 1.41 1.51
Chr6_3 (81 476 083–81 476 101) 0.92 1.11 1.73 1.26
Chr14_1 (51 374 723–51 374 738) 1.52 1.47 1.36 1.42
Chr14_2 (62 203 701–62 203 717) 0.90 1.04 1.58 1.16
Chr14_3 (73 005 461–73 005 479) 1.09 1.13 1.83 1.28
Gray shaded boxes show signature of deletion.
*The positions are based on the UCSC database (hg19 assembly) (http://genome.ucsc.edu/cgi-bin/hgGateway?org=human).
Also see Figure S3.
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tions reported in some subependymoma cases (10), we detected no
deletion in chromosome 14q, but found a partial loss in chromo-
some 6q (Table 2, Figure S2). However, since the latter genomic
portion is one of the known common copy number polymorphisms
(13), it is likely that there are little effects of the deletion on the
tumor onset and growth.
The gene immediately upstream of PAX6 is the gene (RCN1) for
reticulocalbin 1 EF-hand calcium-binding domain (PAX6 and
RCN1 are located in a head-to-head fashion in the genome).There
aresomereportsthatRCN1isassociatedwithtumors(3).However,
the detected deletion in the tumor cells did not affect this gene,
again excluding a potential role for RCN1 in this subependymoma.
There are several reports demonstrating that deletions of tumor-
related regions of PAX6 or dominant negative activity generated by
PAX6 mutations are associated with tumors of glial cell origin. A
57 bp cis-regulatory element named E1E (exon 1 enhancer) in the
ﬁrst exon of PAX6 plays an important role in the expression of
this gene in glioblastoma cell lines (23), and a powerful silencer
(SX250) located between 1518 and 1268 bp from theA of theATG
codon is able to repress the promoter activity of PAX6 in cervical
carcinomaandglioblastomacelllines(22).Puresubependymomas
have a dense glioﬁbrillary background (18). In the patient’s sub-
ependymoma cells, the above regulatory elements are heterozy-
gously deleted. Therefore, it would be one of possible scenarios
thatthesubependymomaoccurredindependentlyinthispatientbut
its unusually large size (maximum diameter of 90 mm) is due to
haploinsufﬁciency of tumor suppressor elements. It is known that
PAX6 proteins with C-terminal deletions have dominant negative
activities (19). In this study, we detected an additional de novo
PAX6 3’-side deletion in patient’s tumor cells. Our PCR analysis of
transcripts suggested that the tumor cell has the two distinct dele-
tions on the same chromosome, although we cannot completely
exclude the possibility that the results are derived from the coexist-
ing normal cells in the tumor tissue. If both deletions were located
on the same chromosome, the effects of PAX6 dominant negative
activity could be neglected because the gene is transcribed from
only the normal allele.
The incidence of all types of intracranial neoplasms is reported
to be 0.008%–0.01% in general population (11).And the incidence
of subependymoma is reported to be 0.5% of all intracranial
neoplasms (15). Therefore the incidence of subependymoma is
deemed to be 0.004%––0.005% in both general population and
aniridia patients.We think that this rareness is related to no reports,
toourknowledge,ofgiantsubependymomasinaniridiapatients.In
addition, aniridia itself is very rare: a frequency of about 1 in
50 000–100 000 live births (2).
It is reported that a compound heterozygous mutation of PAX6
causes severe defects of the brain including the eyes (7). However,
we did not detect any amino acid mutations of PAX6 in the
patient’s tumor or lymphocytes. For epigenetic changes, it is
known that there are many CpG-rich regions in PAX6 (17). These
regionsmaybefrequentlymethylatedintumors,whichcouldaffect
the transcription of PAX6 and tumorigenesis, though we did not
address this issue in the present study because we do not have
neighboringnormaltissue,makingthecomparisonofDNAmethy-
lation status between tumor and normal tissues impossible.
It is noteworthy that although PAX6 defects elicit congenital
aniridiainadominanthereditaryfashion,phenotypesoftheeyeare
sometimes overlooked, especially when the abnormalities are mild
and/or de novo gene defects occur. Our experience suggests that it
wouldbeprudenttopaycloserattentiontoabnormalitiesoftheeye
when presented with large, indolent, benign gliomas.
In summary, we identiﬁed the ﬁrst case of subependymoma con-
comitant with a hereditary disease, familial aniridia. In addition,
the present subependymoma is uncommon in terms of its
extremely large size, anatomical site of development and the
patient’s age and sex.There is a unique registration site, the Danish
Cancer Registry, that has collected data on patients having both
aniridia and cancer since 1943 (20). Although eight patients are
diagnosed as having kidney, lung and digestive tract cancers from
the 136 aniridia carriers, there are no recorded brain tumors (8).
Therefore, the currently detected deletions of PAX6 are unlikely to
be responsible for the subependymoma onset. Given the reports
thatlossofPAX6functionleadstoaberrantproliferationandimma-
ture differentiation of astrocytes in rodents (16), it is reasonable to
assume that the PAX6 deletions contributed to the unusual prolif-
eration of the tumor after its independent initiation. Further reports
of the mechanisms of development of subependymoma are
warranted.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article:
Figure S1. GTG-banded photographs of patient’s chromosomes.
Note that there are no karyotypic abnormalities in the patient’s
lymphocytes.
Figure S2. Chromosomes 6q and 14q that were examined for dele-
tions. Horizontal arrows show the positions of the probes used for
genomic quantitative PCR analyses (see Table 2 in the main text).
The positions (bp) of the BACs (bacterial artiﬁcial clones), RP11-
398K22, RP-202D23, RP-332O9 and RP11-203D6 (1), are also
shown according to the UCSC database (hg19 assembly) (http://
genome.ucsc.edu/cgi-bin/hgGateway?org=human). On each chro-
mosomal region, the hemizygous deletion of the interval between
the denoted BACs is reported in some subependymoma cases (1).
For red symbols at the left of horizontal arrows, see Table 2.
Table S1. Primer sequences and PCR conditions used for PAX6,
PTEN, TP53 and SOX2 screening.
Table S2.Primer and probe sequences used for gQ-PCR.
Table S3.SNP genotypes of PTEN.
Table S4. SNP genotypes of Homo sapiens tumor protein p53
(TP53) gene.
Table S5.Genomic quantitative-PCR of TP53.
Table S6.Genomic quantitative-PCR of SOX2.
Table S7.LOH examination of PAX6.
Please note:Wiley-Blackwell are not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to the
corresponding author for the article.
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